ClinicalTrials.gg
DrugRead study by study

Cabozantinib clinical trials

Also written Cabometyx, XL184, Cometriq and BMS-907351.

studies test it
222
open now
43
in phase 3
21
first study started
2005
ClinicalTrials.gov finds 299 studies for cabozantinib. How that becomes 222 here

Every study that search finds has been read, apart from the 1 newest, to see whether and how it gives cabozantinib. ClinicalTrials.gov counts as of Nov 16, 2026. How drug pages count

  1. 299Found by its intervention search · See all 299 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 265 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
  2. −2
    Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
  3. −1New since the last reading, not read yet
  4. 296Give cabozantinib to participants
  5. −27Observe patients on it, or give it outside a trial
  6. −1Use it as a tool: an imaging tracer or a test of drug response
  7. −7Compare another treatment with it
  8. −39Give it beside what is tested
  9. 222Test it: the count on this site

Get an email when these change. Save the cabozantinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
29 Nov 2012 · COMETRIQ · NDA 203756 (FDA, Drugs@FDA)
European Union
21 Mar 2014 · Cometriq · EMEA/H/C/002640 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Cabozantinib
152
Cabozantinib S-malate
35
Cabozantinib 40 MG
4
cabozantinib-s-malate
3
Cabozantinib tablets
3

Brand

Cabometyx
90
Cometriq
57

Development codes

XL184
84
BMS-907351
37
EXEL-7184
2
EXEL-02977184
2

Studies by the year they started

222 studies that test it; most in 2020 (34)

Studies that test cabozantinib, by start year
YearStudies
20051
20083
20092
20103
20114
201216
201318
20148
20157
20164
201710
201824
201918
202034
202121
202218
202313
20246
20255
20267

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
51
Phase 2
159
Phase 3
21
Phase 4
4
No phase
3

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 36 · Other 186

National Cancer Institute (NCI) (33) · Exelixis (23) · M.D. Anderson Cancer Center (10) · Dana-Farber Cancer Institute (8) · Memorial Sloan Kettering Cancer Center (6) · Massachusetts General Hospital (6) · Bristol-Myers Squibb (5) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (5)

Often tested with

Tested in the same studies.

Nivolumab (36) · Ipilimumab (18) · Atezolizumab (15) · Pembrolizumab (11) · Lenvatinib (7) · Temozolomide (5) · Sunitinib (5) · Erlotinib (4)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 3 phase 3 studies under way

Cabozantinib is the comparator. A study of two new drugs counts under both.

New treatments tested with it · 8 most studied

New when their studies opened, with cabozantinib beside them; studies of each.

Reaching primary completion within a year · 30

Studies that test cabozantinib.

Studies

Open first, then newest update. How each study uses cabozantinib has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.

Testing it · 222

See all 222 studies that test cabozantinib →

Behind its US label · 6 — the studies the FDA label of CABOMETYX describes

From the Clinical Studies section of CABOMETYX (2025-10), as openFDA has it. A study the site does not hold is left out.

Tested on its own · 98 — no other medicine in its arm

Showing 20 of 98. See all 98 →

Tested with established drugs · 21 — they are given beside it

Showing 20 of 21. See all 21 →

Tested in a combination · 103 — another drug in the study is under test too

Showing 20 of 103. See all 103 →

Beside an established treatment under test · 11 — an approved drug, surgery or radiation is what the study tests

Tested with cabozantinib: Surgery or a procedure 7 · Radiation 4 · atezolizumab 3 · Ipilimumab 1 · Nivolumab 1 · Albumin-Bound Paclitaxel 1 · Acarbose 1

Beside a new treatment under test · 20 — a new drug, cell therapy or vaccine is what the study tests

New treatments tested with cabozantinib: clostridium butyricum miyairi 588 strain 2 · CB-839 2 · casdatifan 2 · belzutifan 1 · PT2385 1 · pamiparib 1 · BMS-986527 1 · sapanisertib 1

Beside supportive care · 6 — a supportive treatment or test is studied
One option of several · 2 — a test or a strategy chooses among drugs
As the comparator · 7 — what is tested is compared with cabozantinib
Observed · 27 — patients on it are followed, or it is given outside a trial

Showing 20 of 27. See all 27 →

As a tool · 1 — an imaging tracer or a test of drug response

What changed recently

From the registry's own updates since Oct 18, 2026.

Codes

What other systems call cabozantinib · ClinicalTrials.gg INT005839

  • MeSH (NLM) C558660cabozantinibConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 1C39JW444GCABOZANTINIBConfirmed FDA, NLM, Wikidata
  • RxNorm 1363268Confirmed FDA, Wikidata
  • Wikidata Q795057cabozantinibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C52200CabozantinibOne source FDA
  • DrugBank DB08875One source Wikidata

Also registered as cabozantinib s-malate (UNII DR7ST46X58 · RxNorm 1363267).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.

Start the discussion